| Name | Title | Contact Details |
|---|
The Wound Pros, LLC is a physician-owned Medicare Part B supplier of the industry’s most advanced wound care dressings. As a bonus, Wound Pros offers excellent clinical expertise which gives our patients the best opportunity to heal efficiently. Our vision is to change the way the world treats and manages non-healing wounds. Chronic non-healing wounds can compromise the quality of life for those living in long-term care facilities. The longer a wound remains open or unhealed, the greater the chance of unwanted complications such as infection, hospitalisation, and even amputation. At The Wound Pros, we are dedicated to meeting this challenge head-on with our "Hi-Tech Hi-Touch Approach” to wound care management. Our vision is to change the way the world treats and manages chronic non-healing wounds with better data, better decision making and better documentation.
Almost Family is a leading provider of home health nursing, rehabilitation and personal care services. We are a family of companies with names you can trust. For over thirty years, we have been providing skilled compassionate home health care in our local communities. We bring our expertise into the home - the ideal setting to promote healing, comfort and support to those facing the challenges of aging. Our Senior Advocacy philosophy addresses these challenges in a revolutionary new way. Our clinical team looks beyond the obvious needs of the patient to become advocates in all dimensions of physical, mental and emotional well-being. Our goal is to promote independence, allowing seniors to age in place for as long as possible.
mdINR is a New Windsor, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
More than 20,000 genes make us human. Genes control critical aspects of health and disease — but what controls our genes? Foghorn® Therapeutics ($FHTX) is developing therapies based on a system that directs which genes our cells express, and when, where, and in what order. By manipulating this system with our unique Gene Traffic Control™ platform, Foghorn will change how genes turn “on” and “off.” Unlike approaches that edit genes, this novel way of thinking will alter what our DNA has in store for us—and rewrite destiny for millions of people living with disease. With Gene Traffic Control™ Foghorn is pioneering a new, major class of drug targets to develop unprecedented therapies for cancer and other serious diseases. We have already validated multiple targets, are in the process of developing drug candidates in multiple types of cancer and are beginning to explore other diseases.
Finnzymes, Inc. is a Woburn, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.